Grifols presented AMBAR (Alzheimer Management by Albumin Replacement) top line results phase IIb/III at the Clinical Trials on Alzheimer’s disease congress hold on 27th October in Barcelona.

Dr Antonio Páez, Grifols Medical Director and Head of the AMBAR Clinical Program, confirmed that "the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer’s disease."

The combination of Plasmapheresis, a well known and safe procedure used in plasma exchange, with Albutein® (Albumin) may offer a new treatment pathway for the illness

Fundació ACE in Barcelona and ...


Ahead Therapeutics, a company promoted by ZBM Business Connect in 2017, is preparing for a new funding round to start the clinical trials. The first round amounted to a total of 2 million euros.

The biotech aims to develop new drugs against autoimmune diseases (type 1 diabetes, multiple sclerosis, celiac disease, pemphigus and thyroiditis). Its technology comes from the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA).

ZBM Business Connect, division of ZBM Patents & Trademarks and a CataloniaBio & HealthTech member ...


Reig Jofre has inaugurated the expansion of its plant in Toledo, which has a total of 15,200 square metres. This additional space is used for a new line specialising in penicillin-derivative antibiotics.

The pharmaceutical corporation, led by Ignasi Biosca and a member of CataloniaBio & HealthTech, has invested €10 million in the new facility, which will meet the company's current needs in the national and international markets and allow it to enter the United States market in 2019.

The event, on 23 October, featured President of Spain Pedro Sánchez, President of Castile-La Mancha Emiliano García-Page, Mayor of Toledo Milagros ...


Laboratorios Rubió has invested €4 million in its factory in Castellbisbal (Barcelona) with its sights set on the United States, according to newspaper La Vanguardia. The pharmaceutical corporation led by Pelayo Rubió produces 6 million units of its drugs each year.

"We hope to market our products in North America by 2020," said Pelayo Rubió.

The company saw revenue of €30.7 million in 2017, up 20% from 2016, and is present in 47 countries.

We recommend this video of CataloniaBio & HealthTech interviewing Pelayo Rubió:


The digital therapeutics company Devicare, a CataloniaBio & HealthTech member, and the multinational company Exeltis have signed an agreement to market the Lit-Control® family of products in Spain. 

Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment.

 “We're excited to work with Exeltis to expand the use of Lit-Control® and provide a response to the uncovered medical needs in the area of urology thanks to the constant work with the scientific-medical community and patients” says Rosendo ...